Literature DB >> 3121760

In vitro assessment of antimicrobial agents against Toxoplasma gondii.

C Harris1, M P Salgo, H B Tanowitz, M Wittner.   

Abstract

We have modified a method of quantitating growth of Toxoplasma organisms by measuring incorporation of [3H]uracil into Toxoplasma-infected, differentiated L6E9 rat myocytes and have found that low-dose pyrimethamine (0.1 microgram/ml) and sulfadiazine (25 micrograms/ml) are synergistic. Pyrimethamine at higher concentrations (0.5 and 1.0 micrograms/ml) inhibits uptake to the same degree as the low-dose pyrimethamine-sulfadiazine combination. Spiramycin was effective only at high concentrations (200 micrograms/ml) and with prolonged incubation of greater than 72 h. Clindamycin and several of its analogues, methotrexate and difluoromethylornithine, were all ineffective and showed no additive effect with either pyrimethamine or sulfadiazine. Spirogermanium, an experimental antineoplastic and antiprotozoan agent, was effective only at concentrations close to those toxic to the system. 5-Fluorouracil was effective even at 0.1 microgram/ml. At 0.01 microgram/ml it was synergistic with pyrimethamine (0.1 microgram/ml), and the combination was as effective as high-dose pyrimethamine (1.0 microgram/ml).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3121760     DOI: 10.1093/infdis/157.1.14

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  Activity of pentamidine and pentamidine analogs against Toxoplasma gondii in cell cultures.

Authors:  D S Lindsay; B L Blagburn; J E Hall; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

2.  Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii.

Authors:  J Blais; C Tardif; S Chamberland
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

3.  Paradoxical effect of clindamycin in experimental, acute toxoplasmosis in cats.

Authors:  M G Davidson; M R Lappin; J R Rottman; M B Tompkins; R V English; A T Bruce; J Jayawickrama
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 4.  Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.

Authors:  Andrew J Neville; Sydney J Zach; Xiaofang Wang; Joshua J Larson; Abigail K Judge; Lisa A Davis; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

5.  In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii.

Authors:  M E Fichera; M K Bhopale; D S Roos
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

6.  Effect of clindamycin on pneumonia from reactivation of Toxoplasma gondii infection in mice.

Authors:  G A Filice; C Pomeroy
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

7.  Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.

Authors:  Stéphane Corvaisier; Bruno Charpiat; Cyril Mounier; Martine Wallon; Gilles Leboucher; Mounzer Al Kurdi; Jean-François Chaulet; François Peyron
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Penetration of clindamycin and its metabolite N-demethylclindamycin into cerebrospinal fluid following intravenous infusion of clindamycin phosphate in patients with AIDS.

Authors:  G Gatti; M Malena; R Casazza; M Borin; M Bassetti; M Cruciani
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Localization of azithromycin in Toxoplasma gondii-infected cells.

Authors:  J C Schwab; Y Cao; M R Slowik; K A Joiner
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group.

Authors:  R McLeod; D Mack; R Foss; K Boyer; S Withers; S Levin; J Hubbell
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.